|
|
|
UPCC-13812
|
Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Low-Intermediate Risk Prostate Cancer |
III |
Radiation Therapy, Proton Therapy |
Not Applicable |
|
CALGB-90601
|
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma |
III |
Angiogenesis Inhibitor, Chemotherapy |
cisplatin; gemcitabine; bevacizumab |
|
UPCC 22812
|
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy |
II / III |
Radiation Therapy, Proton Therapy |
Not Applicable |
|
ECOG-E2809
|
Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy |
II |
Hormonal Therapy, Signal Transduction Inhibitor |
bicalutamide; MK2206 |
|
UPCC 06810
|
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy |
I |
Radiotherapy, Signal Transduction Inhibitor |
everolimus |
|
CA186-011
|
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors |
I |
Immunotherapy |
BMS-663513 |
|
UPCC 18809
|
A Trial of Proton Radiation Therapy Using Mild Hypofractionation for Low and Intermediate Risk Adenocarcinoma of the Prostate |
Not Specified |
Radiation Therapy, Proton Therapy |
Not Applicable |
|
UPCC 08809
|
A Trial of Proton Radiation Therapy Using Standard Fractionation for Low and Low-Intermediate Risk Adenocarcinoma of the Prostate |
Not Specified |
Proton Therapy |
Not Applicable |